Mangalam Drugs and Organics Ltd (MANGALAM) is currently trading at 31.80 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Mangalam Drugs and Organics Ltd is a chemical manufacturing company specializing in active pharmaceutical ingredients, perfumery, dye intermediates, and bulk drug intermediates. Established in 1972, its key facilities are located in Vapi and Sangamner. The company has a strong manufacturing setup with significant production capacity expansions over the years, signaling its strategic focus on growth and scale in bulk drugs. Mangalam has demonstrated a commitment to innovation by establishing an Intellectual Property Rights cell and securing WHO approvals for several active pharmaceutical ingredients since 2017. The firm's extensive product portfolio includes chloroquine phosphate, aluminum chloride anhydrous, and other API intermediaries, positioning it as a versatile player in the pharma industry.

Over the past 52 weeks, Mangalam Drugs and Organics Ltd has traded between a low of ₹22.70 and a high of ₹85.99. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Mangalam Drugs and Organics Ltd has a market capitalization of approximately 46.19. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Mangalam Drugs and Organics Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -1.21 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 46.19 Cr, Mangalam Drugs and Organics Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Mangalam Drugs and Organics Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Mangalam Drugs and Organics Ltd is -1.21. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

It disclosed defaults on cash credit facilities with Bank of Maharashtra and Bank of Baroda that have remained overdue beyond 30 days.